Vitamin D and Cognition Trial
A randomised, placebo controlled trial of Vitamin D in older adults with mild cognitive impairment and low vitamin D concentration to prevent cognitive decline and delay progression of cognitive decline.
Professor Nicola Lautenschlager
110 participants
Jun 25, 2007
Interventional
Conditions
Summary
The primary aim of this 18-month randomised, double-blind, placebo-controlled clinical trial is to establish whether vitamin D supplementation can delay progression of cognitive decline amongst older adults with Mild Cognitive Impairment (MCI) who have low vitamin D concentrations (between 12.5 and 50 nmol/L). The main hypothesis of this study is that older adults with MCI randomised to a 18-month treatment with vitamin D will experience significantly less cognitive decline (as measured with the CAMCOG) at the end of the 18-months follow-up than subjects with MCI randomised to placebo. Secondary outcomes of interest for this study include quality of life, gait, balance and muscle strength.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
18-month trial of 1000 IU Vitamin D daily by oral tablet.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12607000321448